Serum Institute of India yesterday said it will begin manufacturing the world’s second malaria vaccine for children approved by the World Health Organization (WHO).
The WHO recommendation is based on pre-clinical and clinical trial data which showed good safety and high efficacy in four countries, at sites with both seasonal and perennial malaria transmission, Pune-based SII said in a statement.
The R21/Matrix-M malaria vaccine has been developed by the University of Oxford and the Serum Institute of India (SII), leveraging Novavax’s adjuvant technology, reports our New Delhi correspondent.
The vaccine is licensed to SII which has already established production capacity for 100 million doses per annum, that will be doubled over the next two years, SII added.
With the approval by the WHO, additional regulatory clearances are expected to follow soon and R21/Matrix-M vaccine doses could be ready to begin wider roll-out as early as next year, it said.